The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors.
R. D. Carvajal
No relevant relationships to disclose
M. M. Gounder
No relevant relationships to disclose
C. M. Coughlin
Employment or Leadership Position - Morphotek
J. Fishel
Employment or Leadership Position - Morphotek
J. Heyburn
Employment or Leadership Position - Morphotek
D. O'Shannessy
Employment or Leadership Position - Morphotek
L. Grasso
Employment or Leadership Position - Morphotek
C. Schweizer
Employment or Leadership Position - Morphotek
J. Parno
Consultant or Advisory Role - Morphotek
L. J. Old
No relevant relationships to disclose
N. S. Azad
No relevant relationships to disclose
L. A. Diaz
No relevant relationships to disclose